OrigAMI-1 Trial at ESMO GI 2025: Amivantamab in mCRC The OrigAMI-1 trial explored the efficacy of amivantamab monotherapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC).

ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #OrigAMI1 #Amivantamab #mCRC #GIOnc